-+ 0.00%
-+ 0.00%
-+ 0.00%

Propanc Biopharma engages European CDMO for GMP production of PRP therapy

PUBT·05/19/2026 12:45:16
Listen to the news
Propanc Biopharma engages European CDMO for GMP production of PRP therapy
  • Propanc Biopharma engaged a Europe-based contract development and manufacturing organization to produce GMP-grade PRP for a planned Phase 1b first-in-human trial.
  • Manufacturing is intended to support a 30-40 patient study in advanced solid-tumor cancers, with a clinical trial application targeted for filing later this year.
  • PRP is designed for once-weekly intravenous dosing, with the study expected to test significantly higher doses than prior compassionate-use experience cited by the company.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605190845PRIMZONEFULLFEED9721207) on May 19, 2026, and is solely responsible for the information contained therein.